Advanced

Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease

Granbom, Elin; Fernlund, Eva LU ; Sunnegardh, Jan; Lundell, Bo and Naumburg, Estelle (2014) In Acta Pædiatrica 103(8). p.840-845
Abstract
Aim: This is the first study to evaluate compliance with the 2003 Swedish national guidelines for prophylactic treatment of respiratory syncytial virus (RSV) in children with congenital heart disease (CHD). We estimated the relative risk (RR) of children with CHD being hospitalised with a RSV infection, studied the extent to which RSV prophylactic treatment with palivizumab corresponded to the guidelines and determined the morbidity of children with CHD who developed RSV infection despite prophylaxis. Methods: This national observational study comprised prospectively registered data on 219 children with CHD treated with palivizumab, medical records on RSV cases and information on hospitalisation rates of children with CHD and RSV... (More)
Aim: This is the first study to evaluate compliance with the 2003 Swedish national guidelines for prophylactic treatment of respiratory syncytial virus (RSV) in children with congenital heart disease (CHD). We estimated the relative risk (RR) of children with CHD being hospitalised with a RSV infection, studied the extent to which RSV prophylactic treatment with palivizumab corresponded to the guidelines and determined the morbidity of children with CHD who developed RSV infection despite prophylaxis. Methods: This national observational study comprised prospectively registered data on 219 children with CHD treated with palivizumab, medical records on RSV cases and information on hospitalisation rates of children with CHD and RSV infection. Results: The calculated RR of children with CHD being hospitalised with RSV infection was 2.06 (950/0 Cl 1.6-2.6; p < 0.0001) compared with children without CHD. Approximately half of the patients (49%) born before the RSV season and 25% born during the RSV season did not start treatment as recommended by the guidelines. Conclusion: Having CHD increased the rate and estimated RR of children being hospitalised with RSV infection. The guidelines were not followed for about half of the children born before a RSV season and a quarter of the children born during a RSV season and need updating. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Congenital heart disease, Palivizumab, Prophylaxis, Respiratory, syncytial virus, Swedish national guidelines
in
Acta Pædiatrica
volume
103
issue
8
pages
840 - 845
publisher
Wiley-Blackwell Publishing Ltd
external identifiers
  • wos:000339986800009
  • scopus:84928207296
ISSN
1651-2227
DOI
10.1111/apa.12658
language
English
LU publication?
yes
id
3fe824ad-8fc7-469c-8504-dcfc0b7a52fd (old id 4665710)
date added to LUP
2014-10-01 07:22:50
date last changed
2017-10-01 04:00:39
@article{3fe824ad-8fc7-469c-8504-dcfc0b7a52fd,
  abstract     = {Aim: This is the first study to evaluate compliance with the 2003 Swedish national guidelines for prophylactic treatment of respiratory syncytial virus (RSV) in children with congenital heart disease (CHD). We estimated the relative risk (RR) of children with CHD being hospitalised with a RSV infection, studied the extent to which RSV prophylactic treatment with palivizumab corresponded to the guidelines and determined the morbidity of children with CHD who developed RSV infection despite prophylaxis. Methods: This national observational study comprised prospectively registered data on 219 children with CHD treated with palivizumab, medical records on RSV cases and information on hospitalisation rates of children with CHD and RSV infection. Results: The calculated RR of children with CHD being hospitalised with RSV infection was 2.06 (950/0 Cl 1.6-2.6; p &lt; 0.0001) compared with children without CHD. Approximately half of the patients (49%) born before the RSV season and 25% born during the RSV season did not start treatment as recommended by the guidelines. Conclusion: Having CHD increased the rate and estimated RR of children being hospitalised with RSV infection. The guidelines were not followed for about half of the children born before a RSV season and a quarter of the children born during a RSV season and need updating.},
  author       = {Granbom, Elin and Fernlund, Eva and Sunnegardh, Jan and Lundell, Bo and Naumburg, Estelle},
  issn         = {1651-2227},
  keyword      = {Congenital heart disease,Palivizumab,Prophylaxis,Respiratory,syncytial virus,Swedish national guidelines},
  language     = {eng},
  number       = {8},
  pages        = {840--845},
  publisher    = {Wiley-Blackwell Publishing Ltd},
  series       = {Acta Pædiatrica},
  title        = {Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease},
  url          = {http://dx.doi.org/10.1111/apa.12658},
  volume       = {103},
  year         = {2014},
}